WAVE Life Sciences (NASDAQ:WVE) Price Target Raised to $27.00 at Mizuho

WAVE Life Sciences (NASDAQ:WVE) had its price objective increased by Mizuho from $22.00 to $27.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has an outperform rating on the stock.

A number of other analysts have also recently weighed in on WVE. Wall Street Zen cut shares of WAVE Life Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. B. Riley Financial lifted their price objective on WAVE Life Sciences from $19.00 to $37.00 and gave the company a “buy” rating in a report on Friday, December 12th. Wedbush upped their price objective on WAVE Life Sciences from $33.00 to $35.00 and gave the company an “outperform” rating in a research note on Friday, March 6th. Truist Financial upped their price objective on WAVE Life Sciences from $36.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of WAVE Life Sciences in a report on Wednesday, January 21st. Fourteen research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, WAVE Life Sciences has an average rating of “Moderate Buy” and a consensus price target of $33.31.

WAVE Life Sciences Price Performance

WVE opened at $12.30 on Wednesday. WAVE Life Sciences has a fifty-two week low of $5.28 and a fifty-two week high of $21.73. The firm’s fifty day moving average price is $13.24 and its two-hundred day moving average price is $11.24. The company has a market capitalization of $2.32 billion, a P/E ratio of -10.08 and a beta of -1.77.

WAVE Life Sciences (NASDAQ:WVE) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.02). The business had revenue of $17.25 million during the quarter, compared to analyst estimates of $15.68 million. WAVE Life Sciences had a negative net margin of 478.35% and a negative return on equity of 85.69%. On average, equities research analysts expect that WAVE Life Sciences will post -1.14 EPS for the current fiscal year.

Insider Activity

In related news, insider Chandra Vargeese sold 3,228 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $13.45, for a total transaction of $43,416.60. Following the completion of the sale, the insider owned 408,246 shares in the company, valued at $5,490,908.70. This trade represents a 0.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Kyle Moran sold 3,588 shares of the business’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $13.45, for a total transaction of $48,258.60. Following the completion of the transaction, the chief financial officer owned 134,385 shares in the company, valued at approximately $1,807,478.25. This trade represents a 2.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 61,748 shares of company stock worth $907,809. Company insiders own 23.98% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. CWM LLC increased its holdings in WAVE Life Sciences by 6,729.0% during the 4th quarter. CWM LLC now owns 2,117 shares of the company’s stock valued at $36,000 after purchasing an additional 2,086 shares in the last quarter. Smartleaf Asset Management LLC raised its position in WAVE Life Sciences by 645.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,243 shares of the company’s stock valued at $38,000 after purchasing an additional 1,942 shares during the last quarter. Bessemer Group Inc. boosted its stake in WAVE Life Sciences by 1,156.3% in the third quarter. Bessemer Group Inc. now owns 9,925 shares of the company’s stock worth $72,000 after purchasing an additional 9,135 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in WAVE Life Sciences by 1,441.6% in the third quarter. Russell Investments Group Ltd. now owns 9,928 shares of the company’s stock worth $73,000 after purchasing an additional 9,284 shares in the last quarter. Finally, Ameritas Investment Partners Inc. grew its holdings in shares of WAVE Life Sciences by 18.7% during the second quarter. Ameritas Investment Partners Inc. now owns 11,444 shares of the company’s stock worth $74,000 after purchasing an additional 1,802 shares during the last quarter. 89.73% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about WAVE Life Sciences

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Mizuho raised its price target on WVE from $22 to $27 and kept an “outperform” rating, representing a large upside vs. the stock’s current level; analyst upgrades like this can drive buying interest and raise investor confidence. Benzinga: Mizuho raises WVE target
• Positive Sentiment: Coverage summarizing Q4 drivers highlights what boosted WAVE in Q4 (revenue strength and institutional attention referenced by fund letters such as Loomis Sayles). Positive quarter commentary and signs of reaccelerating small-cap earnings help justify higher targets and attract momentum investors. Here’s What Boosted Wave Life Sciences Ltd. (WVE) in Q4
• Neutral Sentiment: Analyst roundups and media pieces (e.g., Globe and Mail) are discussing WVE alongside other healthcare names — these summaries increase visibility but do not by themselves change fundamentals. Analysts Offer Insights on Healthcare Companies
• Neutral Sentiment: Market-commentary pieces and stock reviews (AmericanBankingNews) have mentioned WVE alongside peers; useful for context but not a clear directional catalyst. Reviewing BioAtla & WAVE Life Sciences
• Neutral Sentiment: Reports flagged unusually high options activity and a reported increase in short-interest for March, but the published short-interest figures appear inconsistent (0 shares / NaN changes), suggesting a reporting/data error — watch for clarified filings before treating this as a bearish signal. WAVE Life Sciences Target of Unusually High Options Trading

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.